GEN-MKT-18-7897-A
Feb 29, 2016 | Biopharma, Blogs | 0 comments
Traditionally, the pharmacokinetic profile of biotherapeutics such as insulin glargine, adalimumab, trastuzumab and others, used gold standard LBAs to assess dose-response during drug discovery and development. However, LBAs require a specific antibody reagent to be developed for each mAb variant, a process that is often incompatible with the compressed timeframes encountered during the initial stages of drug development. More recently, LC-MS/MS-based methods have come to the forefront as a feasible approach for the quantification of biotherapeutics in biological matrices, with many of these methods relying on proteolytic digestion of the target mAb and quantification of multiple unique signature peptides, which are equivalent to levels of the whole protein. But, to drive the real biological need, we have to quantify the pharmacologically active or free form of the drug to assess safety, efficacy and proper dosing regimen. Here we present a solution to get the best of both technologies: an LBA strategy to capture the active form of the drug; and an LC-MS assay to selectively quantify the free and circulating drug.
In a recent webinar, which is now available on-demand, Holly Lee powerful strategies to tackle complex residue testing. From boosting throughput to fine-tuning method sensitivity, Holly shared key ways to maximize performance across large pesticide panels.
Whether we are raising glasses of rosé in a vineyard in France or enjoying a lager in a casual street restaurant in China, it is likely that the last thing on many people’s minds is the chemical risks from their beverage. Unless you work in food science, then it might actually be the first thing.
As PFAS regulations tighten globally, laboratory managers are navigating a complex economic landscape. Whether operating in a commercial or non- commercial setting, the pressure to deliver accurate, defensible, and timely PFAS data is mounting. At SCIEX we understand that the right technology can turn this regulatory challenge into a strategic opportunity.
Posted by
You must be logged in to post a comment.
Share this post with your network